Cancer Research APC and Open Access: AACR Pricing Logic, Publication and Display-Item Fees, and When Gold OA Is Worth It

Cancer Research does not behave like a standard modern hybrid journal where the copyright-transfer route is effectively free.

The structure on AACR's fee page is:

• gold OA at a single flat APC: $7,000 under CC BY-NC-ND or $8,000 under CC BY

• copyright-transfer publication without an OA APC, with a $2,700 base publication fee

• a $250 fee per display item (figure or table) on the copyright-transfer route

Separately, a nonrefundable $40 manuscript submission fee applies to original research and uninvited review manuscripts submitted since February 17, 2026, unless a bylined author is a validated Active AACR member.

That means authors should compare:

This is why Cancer Research can look more expensive or less expensive depending on how you run the comparison. A manuscript with many figures and tables generates a larger display-item bill, which narrows the gap to the OA APC. For example, a paper with 8 figures and tables would owe $2,700 plus $2,000 in display-item fees before any discount.

This is a journal where the APC is attached to a durable AACR flagship, not a thin prestige signal. Cancer Research still sits in the strong middle between top-glamour cancer titles and lower-tier specialty outlets.

The year-over-year move is positive. Cancer Research is up from 12.5 in 2023 to 16.6 in 2024. That is a meaningful gain and one reason the journal still carries more weight than authors sometimes assume.

AACR's fee page says its membership, editor, grantee, and country-specific discounts apply to total charges excluding any open access fee. For authors choosing OA, membership is therefore not a pricing lever; for authors on the copyright-transfer route it is a 10% discount and a waived submission fee.

Cancer Research is one of those journals where the fee page lists two different kinds of charge, and a single headline number can mislead.

The useful way to read the pricing is:

• AACR supports a hybrid route with a single flat OA APC that does not vary by membership status

• AACR also charges a base publication fee and a per-display-item fee on the copyright-transfer route

• article economics on that route therefore depend on how many figures and tables the manuscript has, and on which discounts apply

That is why a narrow quote-box answer can mislead authors here. If you only ask "what is the APC," you miss the bigger operational question: how far apart are the two actual invoices likely to be once display-item fees and discounts are included?

For short papers with few display items, the copyright-transfer route can still be rational. For papers with many figures and tables and no discount, the difference between the two routes narrows quickly.

For Cancer Research, immediate OA is most defensible when visibility speed has strategic value beyond ordinary discoverability.

That usually means cases like:

• translational cancer-biology work that will be picked up quickly across adjacent oncology subfields

• papers where funder compliance is easier through the final version of record than through later repository handling

• work from teams that would already owe substantial display-item fees under copyright transfer, so the incremental jump to OA is modest

What usually does not justify the premium:

• papers with uncertain mechanistic fit

• manuscripts likely to be revised heavily after editorial pushback

• situations where the authors are using OA as a substitute for stronger targeting discipline

The cost discussion becomes much clearer once the manuscript is actually a Cancer Research paper. Before that, pricing is just noise attached to a journal that may still say no on scope.

In manuscript-readiness review, the billing question is rarely the real mistake.

The real mistake is targeting Cancer Research with a manuscript that is:

• descriptive rather than mechanistic

• translational but too thin on biology

• solid oncology work that really belongs in a more clinically oriented journal

What usually works here:

• mechanistic cancer biology with translational consequence

• papers that teach the field something biologically durable

• stories that are stronger than routine specialty-journal work but not necessarily broad enough for Cancer Cell

That is why the APC decision should follow the fit decision, not the other way around.

For Cancer Research APC, the right way to think about cost is:

• OA route: $7,000 (CC BY-NC-ND) or $8,000 (CC BY), the same for members and nonmembers

• copyright-transfer route: not zero, because a $2,700 base fee and $250 per display item apply

That means the useful comparison is not APC versus free. It is APC versus base fee plus display-item fees.

Do not reduce the Cancer Research access decision to one copied APC number. Verify the current article route, license, author eligibility, institutional agreement, funder requirement, tax, and invoice responsibility from official sources.

In our editorial analysis, the recurring failure pattern is fee-to-bill collapse: a list price is presented as the final amount for every author. That can be wrong because route, agreement, tax, waiver, and timing differ.

Decision artifact

Save a dated citation to the official page, note the manuscript article type, identify the paying entity, confirm eligibility in writing where needed, and distinguish “verified,” “conditional,” and “unknown.” This makes the page useful even when volatile prices change and prevents a permanent SEO claim from becoming a financial promise.